NCT05673148
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
At risk: Enrollment reduced 60%.
See at-risk trials from Alliance for Clinical Trials in Oncology
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 28 versions: 27 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 189 → 195 locations
- Notable Eligibility criteria shortened, about 5 words
- Study sites: 187 to 189
- Secondary endpoints: details revised at 3 of 3 entries
- Publications: details revised at 2 of 2 entries
- Notable Enrollment reduced: 364 → 146 participants
- Phase changed: Phase 3 → Phase 2
- Site details revised at 11 of 187 sites
Notable Phase: Phase 3 to Phase 2v25 Show 5 more changesShow less
- Enrollment target: 364 to 146
- Eligibility criteria expanded, about 315 words
- Study description expanded, about 44 words
- Site details revised at 1 of 187 sites
- Study title shortened, about 1 word
- Minor Study sites: 186 to 187v24
Show 21 earlier versionsHide 21 earlier versions
- Minor Study sites: 185 to 186v23
- Minor Study sites: 183 to 185v22
- Minor Study sites revised (183)v21
- Minor Study sites: 182 to 183v20
- Minor Site details revised at 8 of 182 sitesv19
- Minor Study sites: 177 to 182v18
- Minor Study sites: 176 to 177v17
- Minor Site details revised at 3 of 176 sitesv16
- Minor Study sites: 166 to 176v15
- Minor Study sites: 148 to 166v14
- Minor Study sites: 130 to 148v13
- Notable Start date: Jan 10, 2023 to Oct 9, 2023
- Primary completion date: Jun 3, 2028 to Jul 3, 2028
- Site details revised at 125 of 130 sites
- Minor Study sites: 125 to 130v11
- Minor Study sites: 116 to 125v10
- Minor Study sites: 108 to 116v9
- Minor Study sites revised (108)v8
- Minor Study sites: 97 to 108v7
- Minor Study sites: 82 to 97v6
- Minor Study sites: 59 to 82v5
- Minor Study sites: 11 to 59v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 11
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Patients undergo TAT on study, consisting of SABR with or without surgical resection and/or microwave ablation. Patients also receive SOC chemotherapy on study. Patients also undergo CT or MRI or PET/CT scans throughout the trial.
Patients receive SOC chemotherapy on study. Patients also undergo Patients also undergo CT or MRI or PET/CT scans throughout the trial.
Procedures: Stereotactic Ablative Radiotherapy, Resection, Microwave Ablation, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Drugs: Chemotherapy
Sites
195 sites in 2 countries
United States 194, Canada 1